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ABSTRACT
Background. Despite optimal surgical treatment and
modern adjuvant therapies, 50% of patients diagnosed with
colorectal cancer die within 5 years. Immunotherapy offers
an appealing complement to traditional chemotherapy,
with possible long-term protection against tumor recur-
rences through immunological memory. We have
conducted a pilot study of a novel adoptive immunother-
apy, using autologous, in vitro expanded lymphocytes
isolated from the tumor-draining sentinel lymph node.
Study Design. Sentinel nodes were recovered from 16
patients with disseminated or locally advanced, high-risk
colorectal cancer. Single-cell suspensions of sentinel-node-
acquired lymphocytes were clonally expanded in vitro in
the presence of autologous tumor extract and returned as a
transfusion. Patients were followed with clinical and
radiological evaluations. Long-term survival was compared
with traditionally treated controls.
Results. Sentinel-node-acquired CD4
? Th1-lymphocytes
could be clonally expanded in vitro and safely administered
to all 16 patients without side-effects. In four out of nine
stage IV patients, complete tumor regression occurred.
Median survival time in the stage IV patients (n = 9) was
2.6 years, as compared with 0.8 years in conventionally
treated controls. A dose-dependent effect with regards to
reduced tumor burden and long-term survival was observed.
Conclusion. Sentinel-node-based adoptive immunother-
apy is feasible; the method has shown no apparent side-
effects and appears to convey therapeutic antitumor effects.
Further studies are justiﬁed to determine its efﬁcacy and
precise role in the treatment of colorectal cancer.
Colorectal cancer is the third most common cause of
cancer mortality.
1 Despite surgery and adjuvant therapies,
half of patients have recurrences and ultimately die within
5 years from diagnosis.
2 Patients with locoregional lymph
node metastases (stage III) have an approximately 60% 5-
year survival after surgery and adjuvant therapy, but when
distant metastases are present the 5-year survival rate is
less than 10%.
3 The established adjuvant treatment in stage
III patients was 5-ﬂuorouracil (5-FU)-based chemotherapy
at the time of the study, which has been reported to
improve absolute 5-year survival at most by 10%.
4,5 In
stage II patients the statistically signiﬁcant, absolute
improvement in survival with chemotherapy is even
smaller, and it is not generally recommended to all stage II
patients.
6 However, 20% of patients who are classiﬁed as
being lymph node negative will suffer from recurrent dis-
ease.
3 Attempts have been made to identify tumor
characteristics conferring high risk of recurrence in order to
offer adjuvant treatment exclusively to stage II patients
with such tumors. Still, it is not clear whether this strategy
is successful, and no consensus exists on which tumor
characteristics are the most useful to predict relapse.
The most important negative prognostic factor for sur-
vival of colorectal cancer is the detection of lymph node or
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7 Understaging is likely, since it is widely accepted
that accurate staging of colon cancer is difﬁcult and criti-
cally dependent on the number of lymph nodes analyzed by
the pathologist.
8 The sentinel node, originally deﬁned in
penile carcinoma, is the ﬁrst lymph node to receive lym-
phatic drainage from a tumor.
9 Sentinel node detection and
analysis have recently been applied in colon cancer,
improving staging considerably.
10,11 To test if T-lympho-
cytes were components of a natural, tumor-evoked immune
response originating in tumor-draining lymph nodes, we
analyzed sentinel nodes from patients with urinary bladder
cancer and colon cancer.
12–14 In those nodes we identiﬁed
tumor-reactive lymphocytes, secreting interferon (IFN)-c
upon stimulation with tumor antigen in addition to dose-
dependent proliferation, when assessed ex vivo directly
after dissection. The sentinel node was the predominant
location for activation and expansion of tumor-reactive
lymphocytes.
Vaccination trials have shown promising results in
colorectal cancer patients.
15–17 Adoptive immunotherapy,
including collection and expansion of autologous tumor-
reactive lymphocytes with retransfusion to the patient, has
been explored in malignant melanoma, and recently a ret-
roviral gene therapy approach using a melanoma-speciﬁc
T-cell receptor has been tried.
18,19 Immunotherapy offers
an appealing complement to traditional chemotherapy,
with possible long-term protection against tumor recur-
rences through immunological memory. Hitherto, the
majority of studies have used peripheral blood or tumor-
inﬁltrating lymphocytes as the source of CD8
? cytotoxic T
lymphocytes for activation and expansion.
We became interested in the speciﬁc b-cell destruction
observed in a mouse model, after transfer of in vitro b-cell
surrogate antigen-activated CD4
? Th1-cells.
20 In another
mouse model, presence of CD4
? T-helper cells appeared
necessary for the effective functioning of cytotoxic T-
lymphocytes and for the development of memory cells.
21
Furthermore, CD4
? T-helper-1 cells mature due to the
expression of the transcription factor T-bet, which also
induces production of IFN-c necessary for effective
defense against metastases.
22,23 We reasoned that tumor-
activated CD4
? Th1-cells harvested from the natural
source, the tumor-draining sentinel node, may after in vitro
expansion elicit a similar response in patients with dis-
seminated cancer, eradicating metastatic cells which
express antigens derived from the tumor. In the present
study we obtained sentinel nodes from patients with dis-
seminated or locally advanced, high-risk colon cancer with
aggressive tumor characteristics such as ulcerations, vas-
cular or perineural invasion. Sentinel or metinel (i.e.,
metastasis-draining lymph node) node-acquired lympho-
cytes were expanded ex vivo by stimulation with
autologous tumor extract and retransfused into the patient
with the primary objective of investigating feasibility,
toxicity, and side-effects and secondarily to evaluate its
effect on long-term tumor progression.
14
METHODS
Study Design
This was a pilot study, approved by the Local Ethical
Committee at Karolinska Institute, Stockholm, Sweden.
The inclusion criterion was operation due to metastatic or
locally advanced, high-risk colon cancer, with peroperative
sentinel node detection.
Patients
Sixteen consecutive patients diagnosed with colon can-
cer (six women and 10 men, average age 62 years) were
included from September 2003 and followed with regular
controls at the hospital until February 2008 (Table 1).
Patients were informed both by surgeons and oncologists
not participating in the study, and each patient gave
informed consent. Patients were histopathologically clas-
siﬁed as stage II, III or IV, as deﬁned by American Joint
Committee on Cancer (AJCC) criteria. All ﬁve patients
with stage II disease were identiﬁed as high risk according
to the vascular emboli, lymphatic invasion, and perineural
invasion (VELIPI) criteria.
24 They had aggressive tumor
characteristics such as ulcerations, vascular or perineural
invasion. Three patients (nos. 10, 13, and 15) had previ-
ously been treated for primary colon cancer and now had
recurrent disease in the liver (nos. 10 and 13) or abdomi-
nally (no. 15). None of the patients had received any organ
transplant, nor had a history of steroid treatment or other
immunosuppressive regimes.
Sentinel Node Detection
Identiﬁcation of sentinel nodes was performed intraop-
eratively using the sentinel node technique.
10 Mobilization
of the colonic tumor or metastasis was conducted accord-
ing to standard surgical procedures. Patent blue dye
(Guerbet, Paris) was injected superﬁcially in the serosa
around the tumor or in the tissue surrounding the metas-
tasis. One to three-ﬁrst draining lymph nodes were colored
blue, usually within 5 min. These sentinel nodes were
marked with sutures and removed when the resection was
complete (Fig. 1). Approximately half of each sentinel
lymph node was retained for analysis and expansion, the
1748 M. Karlsson et al.other half being processed for routine histopathological
examination by hematoxylin and eosin. A piece of the
tumor or metastasis, including the invasive margin, was
used for antigen preparation.
Cell Culture
The sentinel node material was retained on ice and
thereafter in AIM V
 media (Invitrogen) in all subsequent
TABLE 1 Participant characteristics
Patient no. Age/sex AJCC stage/TNM
classiﬁcation
at surgery
Infused cells
(910
6)
CD/CD8
a IFN-c (pg/ml) IL-4
(pg/ml)
Response Overall
survival
(months)
1 66/M IIA/T3N0M0 152 96/1.4 1411 6 SD 42
2 74/M IIA/T3N0M0 63 64/22 ND ND SD
b 44
3 71/M IIA/T3N0M0 50 74/15 2091 5 SD 44
4 67/F IIA/T3N0M0 8 15/51 ND ND SD 45
5 67/M IIA/T3N0M0 4 92/0.2 ND ND SD 46
6 58/F IIIA/T2N1M0 16 77/18 417 9 SD 36
7 64/F IIIC/T3N2M0 113 64/25 ND ND SD 49
8 61/F IV/T2N1M1 1 3.7/35 ND ND SD
c 6
9 82/F IV/T3N2M1 12 98/0.1 ND ND —
d 6
10 54/M IV/T3N1M1 40 37/24 ND ND SD 51
11 33/M IV/T4N2M1 40 87/3.3 908 19 SD
e 12
12 66/M IV/T3N1M1 40 46/27 764 6 PR
f 15
13 74/M IV/TXNXM1 170 73/22 142 18 CR
g 31
14 42/F IV/T4N0M1 80 66/11 ND ND CR
h 40
15 47/M IV/TXNXM1 80 24/16 ND ND CR 51
16 65/M IV/T3N2MX 270 82/15 ND ND CR
i 51
TNM tumor-node-metastasis
Complete response (CR), partial response (PR), and stable disease (SD) as evaluated by WHO criteria at follow-up
a The numbers represent the percentage of CD4- and CD8-positive cells detected with FACS
b The patient received lymphocyte transfusion 1 month after surgery, when he displayed stable disease for 6 months. Due to the appearance of
liver metastases after 6 months, he was treated with chemotherapy and later liver surgery. The patient developed recurrent disease after another
30 months
c Patient 8 displayed regression of liver metastases and decreased CEA levels, but radiological evaluation did not fulﬁll the WHO criteria for
partial response and the patient was classiﬁed as having stable disease. The patient’s physical condition improved following immunotherapy,
with regain of appetite and weight, and from being bedridden to daily walks and kayaking (WHO class I). At this time she suddenly died at home.
Relatives opposed the performance of autopsy, but it is likely that heart attack or lung embolus was the cause of death
d The patient was an 82-year-old lady with cardiopulmonary disease, known and treated prior to her development of colon cancer. At the time of
diagnosis of colon cancer she had metastases in liver and spleen, and bilateral lung metastases. After immunotherapy she lived in a geriatric ward
and died 5 months later. No autopsy was done. Lost to follow-up
e The patient was a young man who presented as an emergency with colonic obstruction and metastatic disease (intraperitoneal and liver). The
primary tumor causing the obstruction was resected. The tumor responded initially, with regression of liver and peritoneal metastases. In
addition, ascites disappeared with decreased S-CEA levels and enhanced general well-being. After 9 months the disease progressed and he died
3 months later
f After immunotherapy the patient achieved partial regression of metastases to the liver and lungs. After 7 months he developed a metastasis to
the vertebral column. One month later the lung metastases increased in size and after further 4 months the liver metastases increased in size and
number. He died 14 months after the immunotherapy
g A 74-year old man who initially had surgery due to a sigmoid colon cancer, stage II. Fifteen months later he developed a solitary liver
metastasis. Following liver surgery he had adjuvant sentinel-node-based immunotherapy. CEA was stable and he showed no signs of recurrence.
One month later he developed pancreatic cancer and died after a further 13 months
h The patient displayed complete response after immunotherapy; relapse occurred after approximately 3 years, with metastases to the liver, and
after 40 months the patient died from her disease
i The patient had multiple lymph node metastases (n = 16) and presented immediately after primary surgery with liver metastasis. Following
incomplete resection of the liver metastasis, he received sentinel-node-based immunotherapy, which resulted in complete response of remaining
metastases. Two years later he developed additional liver metastases and received further immunotherapy based on expansion of peripheral blood
lymphocytes using autologous tumor extract
Sentinel-Node-Based Immunotherapy of Colon Cancer 1749steps. Single-cell suspensions of sentinel node lymphocytes
were obtained through gentle homogenization in a loose-ﬁt
glass homogenizer, following which cells were washed
twice in medium. The sentinel node lymphocytes were
dispersed into cell culture ﬂasks at a density of 4 million
cells/ml and supplemented with interleukin-2 (IL-2) (Pro-
leukin
, Chiron). Autologous tumor extract was prepared
by homogenization with an Ultra Turrax in 5 volumes (w/
v) of 2 9 phosphate-buffered saline (PBS) followed by
denaturation for 5 min at 97C. Three to four days after
initiation of the cell culture, autologous tumor extract was
added at dilution of 1/100 (v/v). For long-term culture the
cells were retained in a cell incubator at 37C and 5% CO2,
and IL-2 (Proleukin
, Chiron) was added every 3–4 days.
After approximately 3 weeks the cell cultures were
restimulated through the addition of autologous tumor
extract at dilution of 1/100 (v/v). For efﬁcient antigen
presentation, autologous peripheral blood mononuclear
cells (PBMC)were collected using Ficoll-Paque PLUS
(Amersham Biosciences, GE Healthcare), irradiated with
2,500 rad, and added to the cell cultures. The day before
transfusion, viable cells from the cultures were retrieved
using Ficoll-Paque PLUS (Amersham Biosciences, GE
Healthcare). On the day of transfusion, the cells were
washed twice in saline solution (sodium chloride Baxter
Viaﬂo 9 mg/ml, Baxter) and then transferred to a sterile
plastic bag containing 100–200 ml saline solution and 1%
human serum albumin (Baxter). Investigations to exclude
microbial growth were performed prior to transfusion.
Infusion of the cells back into the patient was performed
according to the blood transfusion guidelines of the
hospital.
Immunological Evaluation
The proliferative response upon stimulation with autol-
ogous tumor homogenate in PBMC was investigated using
a tritium-labeled thymidine incorporation prolifera-
tion assay. PBMC were obtained by density centrifugation
(Ficoll-Paque, Amersham Biosciences, GE Healthcare).
Cells were resuspended and washed twice in Roswell Park
Memorial Institute (RPMI) 1640 (Life Technologies)
containing 2.5% fetal calf serum (FCS) (Life Technolo-
gies) before culture in RPMI 1640 medium containing 10%
human AB serum (Sigma), 1% penicillin–streptomycin
(Sigma), and 1% glutamine (Sigma). Lymphocytes were
incubated at 3 9 10
5 cells/well in a 96-well plate and
stimulated with tumor homogenate diluted 1/100 or 1/10
(v/v) or with the general T-lymphocyte mitogen Conca-
navalin A (Con A, 10 lg/ml; Sigma) in triplicate.
Proliferation was measured on day 2 (Con A) and days 5, 6,
and 7 (tumor homogenate) by adding 1 lCi
3H-thymidine/
well (Amersham) 18 h prior to harvesting. Samples were
subjected to scintillation counting. Stimulation of PBMC
for measurement of IFN-c secretion was performed in 96-
well plates with 3 9 10
5 cells/well in triplicate with tumor
FIG. 1 Perioperative identiﬁcation of sentinel node(s). Identiﬁcation
of sentinel nodes was performed by subserosal injections of Patent
blue dye at four sites around the tumor (a). Usually within 5 min, one
or more blue-colored lymph nodes appear in the mesentery (b).
Hypothetical scheme of activation of tumor-reactive lymphocytes in
the sentinel node (c). In the tumor there is a rapid turnover of cells,
and lack of oxygen and nutrition, causing a hostile environment which
attracts macrophages and dendritic cells. These professional antigen-
presenting cells (APC) phagocytose debris from tumor cells and then
migrate via the lymph vessels to the draining sentinel node. In the
sentinel node the APCs present tumor-derived peptides, thus activat-
ing tumor-reactive T-lymphocytes
1750 M. Karlsson et al.homogenate diluted 1/10 and 1/100 (v/v), or Con A (10 lg/
ml, Sigma). The amount of secreted IFN-c was measured
by enzyme-linked immunosorbent assay (ELISA, Human
IFN-c Duoset; R&D Systems) on culture supernatants in
pooled triplicate samples. At the end of ex vivo culture of
sentinel-node-acquired lymphocytes the amount of IFN-c
and IL-4 secreted into the supernatant was measured in
triplicate by ELISA (Human IFN-c Duoset and Human IL-
4 Duoset, R&D Systems).
Flow Cytometry Analyses
Cells from the sentinel node, nonsentinel node, periph-
eral blood leukocytes (PBL), and from the tumor itself
were characterized by ﬂuorescence-activated cell sorting
(FACS). Samples were analyzed by FACS regularly from
the cultured sentinel-node-acquired lymphocytes. Cells
were incubated for 30 min in PBS supplemented with 2%
FCS and 0.05% NaN3 (FACS buffer) with antibodies
against markers for immune cell subpopulations and for
lymphocyte activation. Antibodies conjugated with ﬂuo-
rescein isothiocyanate (FITC) speciﬁc for the following
markers were used: CD69, HLA-DR, CD45RA, CD25;
conjugated with phycoerythrin (PE): CD62L, CD19,
CD45RO, CD56, conjugated with peridinin-chlorophyll-
protein (PerCP): CD8, CD3; conjugated with allophyco-
cyanin (APC): CD4, CD14, CD8. The Vb-TCR repertoire
was examined using the Beta mark kit (Beckman Coulter),
5 9 10
5 cells/tube being stained in 10 ll of the eight dif-
ferent vials containing mixtures of FITC, PE, and dual-
color FITC-PE-conjugated TCR Vb antibodies. In addition,
direct conjugated antibodies CD8 PerCP and CD4 APC
were added to each tube. The presence of tumor cells was
examined by intracellular staining for cytokeratin 20. Cells
were permeabilized in FACS buffer containing 0.3%
saponin, incubated for 30 min with anti-human cytokeratin
20 (Dako Cytomation), washed, and stained with FITC-
conjugated donkey anti-mouse immunoglobulin G (IgG)
for 30 min (Jackson ImmunoResearch).
Chemotherapy
Six patients (nos. 1, 3–5, 8, and 9) did not receive any
chemotherapy. Patients 13 and 15 received chemotherapy
after primary surgery. They later developed metastases (at
least 1 year after chemotherapy) and at that time had
sentinel-node-based immunotherapy, without any further
chemotherapy. Patients 2, 6, 7, 10–12, 14, and 16 were
treated with immunotherapy followed by chemotherapy
(ﬁrst-line 5-ﬂuorouracil ? leucovorin). Adverse effects
related to chemotherapy and limited patient compliance led
to early termination of chemotherapy treatment in four
patients (nos. 6, 10, 12, and 14). Two stage IV patients
received no chemotherapy treatment (nos. 8 and 9), and
two patients received chemotherapy 1 year prior to
immunotherapy (nos. 13 and 15).
Follow-up
Patients were clinically evaluated according to the reg-
ular follow-up program after diagnosis and treatment of
colon cancer in Sweden. Follow-up visits usually took
place 3, 6, 12, and 18 months after cell transfusion. On
each of these occasions, general condition was estimated
and the amount of carcinoembryonic antigen (CEA) in
serum was measured. Every 6 months the patients were
also examined for presence of liver and lung metastases by
ultrasound, X-ray or computer tomography (CT) scan, or
ﬂuorodeoxyglucose positron emission tomography (FDG-
PET). Assessment of clinical response was made by com-
parison of radiographic measurements and physical
examinations before and after treatment using World
Health Organization (WHO) criteria. Complete disappear-
ance of all evaluable disease was deﬁned as complete
response (CR). Partial response (PR) was deﬁned as
decrease of 50% or more in the sum of the products of
perpendicular diameters of all measurable lesions. Stable
disease (SD) was deﬁned as no signs of tumor progression
between two consecutive CT evaluations of measurable
remaining disease or lack of additional (stage IV) or no
appearance of metastatic lesions (stage II and III).
Statistical Analysis
The number of cells received by patients with SD and
PR disease was compared with the number of cells
received by patients classiﬁed as CR using Wilcoxon’s
rank-sum test. All patients in the Stockholm colon cancer
registry diagnosed during the year 2003 with stage IV
(n = 174) were used as a control group for cumulative
survival comparison. The survival time of the nine stage IV
patients treated with immunotherapy and the control stage
IV cohort were plotted in an actuarial survival diagram.
Survival times were compared using log-rank (Mantel–
Cox) analysis. P\0.05 was considered signiﬁcant.
RESULTS
Expansion of Sentinel-Node-Acquired Lymphocytes
Sixteen patients with colorectal cancer were studied
(Table 1). In all patients, 1–3 (average 2.1) sentinel node(s)
were identiﬁed intraoperatively (Fig. 1) by peritumoral
injections of Patent blue dye (Guerbet, Paris). We
Sentinel-Node-Based Immunotherapy of Colon Cancer 1751cultivated sentinel-node-acquired lymphocytes by stimu-
lation with autologous tumor extract, to ensure clonal
expansion of tumor-reactive CD4
? Th1-lymphocytes. Low
amounts of interleukin-2 were added to overcome immu-
nosuppression. The average number of sentinel-node-
acquired lymphocytes at the start of expansion was 115.2
million cells (range 3.6–509 million, median 71 million).
Cells were continuously monitored and characterized by
ﬂow cytometry (FACS) during expansion (Fig. 2a). The
CD4
?/CD8
? ratio at the start was 4.8 on average (range
0.36–10, median 5.0), indicating a natural enrichment of
CD4
? T-helper lymphocytes in sentinel nodes when com-
pared with the CD4/CD8 ratio in peripheral blood (range
1.0–2.5). In addition, B-lymphocytes (CD19
?) and a small
number of natural killer (NK) cells (CD56
?, CD3
-) were
present in sentinel nodes (not shown). The cells were held
in culture for 36.5 days on average (range 23–58 days).
Initially, the total number of cells decreased. B-lympho-
cytes disappeared almost completely (37.6% at start, 0.4%
at transfusion), and the number of CD8
? T-cytotoxic cells
diminished. This procedure mainly promoted the expansion
of T-helper lymphocytes, since the average CD4/CD8 ratio
at transfusion was 86.6 (Fig. 2a, Table 1). However, in
some cases (Table 1) a substantial number of CD8
? T-
cytotoxic lymphocytes developed. The transfused cells
were heterogenous with respect to CD62L expression, but
uniformly CD45RO positive, indicative of a mixed mem-
ory-cell population, comprising both central and effector
memory cells (Fig. 2a).
ELISA Results
In six cases (Table 1), the expanded T-lymphocytes
were functionally tested before transfusion by measuring
the levels of the Th1 cytokine IFN-c and the Th2 cytokine
IL-4 in the cell culture supernatants (Fig. 2b). The average
level of IFN-c was 956 pg/ml and the average level of IL-4
was 11 pg/ml, indicating that the expanded T- lymphocytes
were functional and Th1 responsive. Restimulation after
about 3 weeks with autologous tumor antigen and autolo-
gous PBMCs, acting as antigen-presenting cells, resulted in
further clonal expansion of tumor-reactive T-lymphocytes
as assessed by investigating the T-cell receptor Vb reper-
toire of sentinel-node-acquired lymphocytes before and
after restimulation (Fig. 2c).
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FIG. 2 Sentinel node lymphocytes are enriched in T-helper cells and
secrete IFN-c after ex vivo cell culturing. At the start and end of ex
vivo cell culture, sentinel-node-acquired lymphocytes were charac-
terized by ﬂow cytometry with regards to activation and memory cell
markers (a). The amount of IFN-c and IL-4 secreted into the
supernatant was measured by ELISA (b). The data presented is from
patient 15 on the day prior to transfusion, which in this case
corresponds to 40 days of ex vivo cell culture. T-cell receptor Vb
repertoire of expanded sentinel-node-acquired lymphocytes (c). In
patient 7 the T-cell receptor Vb repertoire was investigated by ﬂow
cytometry at the start and end of ex vivo cell culturing. Clonal (Vb
22) expansion of CD4
? T-helper lymphocytes was detected
1752 M. Karlsson et al.Retransfusion and Toxicity
On average, 71 million clonally expanded autologous
tumor-reactive T-lymphocytes were retransfused to each
patient (Table 1). No toxic side-effects, such as fever,
chills, malaise, severe ﬂuid retention, pulmonary edema or
respiratory distress, were observed.
Clinical Outcome
The patients were followed for 36 months on average
(range 6–51 months) and monitored in accordance with the
Swedish colorectal cancer follow-up protocol. The patients
with distant metastases (stage IV) responded to treatment,
with either extended periods of stable disease (n = 4),
partial response with diminished tumor burden (n = 1) or
complete response with no detectable remaining tumor
(n = 4) (Table 1). Patient no. 14 (Table 1) with dissemi-
nated disease had a large sigmoid tumor resected en bloc,
involving the left ovary, the left uterine tube, and the upper
part of the uterus. She had metastases in both liver lobes.
The metastases regressed completely after immunotherapy,
as demonstrated by CT scan (Fig. 3a) and FDG-PET
(Fig. 3b). Patient no. 12 (Table 1) displayed disseminated
disease with large liver metastases and multiple lung
metastases. The primary tumor was resected because of
obstructive symptoms, and immunotherapy followed after
5 weeks. Partial response with marked regression of liver
metastases and disappearance of several lung metastases
occurred within 3 months (Fig. 3c). Notably, the stage IV
patients responding with SD and PR received signiﬁcantly
fewer cells than the four patients with CR (P\0.05)
(Fig. 3d), thus indicating a dose response.
The cumulative survival of the nine treated stage IV
patients was compared with all stage IV cases in the Stock-
holm region during the year of 2003 (n = 174). The median
survival of stage IV patients who received immunotherapy
was 2.6 years compared with 0.8 years median survival of
the control group, and there was a tendency towards
increased cumulative survival (P = 0.06) (Fig. 4e). Six
patients have died, of whom ﬁve were classiﬁed as
responders with stable disease (nos. 8 and 11), partial
response (no. 12) or complete response (nos. 13 and 14).
Patient 9 was lost to follow-up. Patients no. 13 and 14 were
classiﬁed as complete responders after immunotherapy.
However, patient 14 developed metastases to the liver after
3 years and died after 40 months. Patient no. 13 died from
pancreatic cancer without any signs of recurrent colon can-
cer.DetailsregardingdeadpatientsarepresentedinTable 1.
Five patients classiﬁed as stage II, with high-risk tumor
characteristics, were included in the study (Table 1). One
stage II patient (no. 2) developed liver recurrences, which
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FIG. 3 Patient outcome. Computer tomography (CT) of patient 14,
showing a metastasis measuring 12.7 9 13.0 9 13.3 mm
3 in the liver
at time of treatment (a, left panel). Follow-up CT scan 3 months after
treatment showed no signs of liver metastasis. (a, right panel). FDG-
PET of patient 14 at time of treatment revealed additional FDG-
positive metastases in the liver, indicated by arrows (b, left panel).
Follow-up FDG-PET scan 6 months after treatment without any signs
of FDG-positive metastases, indicating complete remission; the only
remaining FDG uptake is seen in the kidneys (b, right panel).
Imaging of lung metastases. In patient 12, bilateral lung metastases
were detected on computer tomography (CT) prior to surgery (c, left
panel). Follow-up CT scan 3 months after cell transfusion revealed
complete remission of some metastases and signiﬁcant decrease in the
remaining metastases (c, right panel). Dose-dependent response in the
stage IV patients (d). Complete response was seen in four of the nine
stage IV patients. Patients with complete response were transfused
with an average of 150 million cells, a signiﬁcantly (P\0.05) larger
number of cells than the average of 27 million cells transfused in
patients with partial response or stable disease
Sentinel-Node-Based Immunotherapy of Colon Cancer 1753responded to immunotherapy with regression of metastases.
He is now free of recurrences and classiﬁed as having stable
disease. The other patients with high-risk stage II disease
(nos. 1 and 3–5) and the patients with stage III (nos. 6 and 7)
have had no signs of recurrences and are thus classiﬁed as
stable disease according to their original status.
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FIG. 4 Treatment responses after sentinel-node-based adoptive
immunotherapy. Immune response upon stimulation with autologous
tumor extract could be detected in peripheral blood leukocytes from
patient 10 (a and b). Patient 10 had, 10 months earlier, received a
transfusion of ex vivo expanded sentinel node lymphocytes. The
proliferative response (a) was measured by
3H-thymidine incorpora-
tion assay (day 5), and the amount of IFN-c secreted into the
supernatant was measured by ELISA (day 6) (b). Stimulation with
autologous tumor extract diluted 1/100 or 1/10 or in medium alone
(0). In patient 16 the proliferative response in peripheral blood after
transfusion, at 10 months (c) and 42 months (d), was investigated by
3H-thymidine incorporation assay. At 10 months, peak proliferation
upon stimulation with autologous tumor homogenate (diluted 1/100
and 1/10) was approximately 10,000 cpm (day 7) (c). By 42 months
the peak proliferation had increased to 47,000 cpm (day 6) upon
addition of autologous tumor homogenate (diluted 1/100 and 1/10)
(d). Proliferation in response to addition of allogeneic tumor
homogenate from patient 5 was also investigated (‘‘CC pat 5 1/
100’’ and ‘‘CC pat 5 1/10’’), resulting in peak proliferation of
31,000 cpm (day 6) (d). Increased survival in stage IV patients treated
with sentinel-node-based adoptive immunotherapy (e). Actuarial
survival curves were obtained by comparing survival among patients
with stage IV receiving adoptive immunotherapy (9 patients) versus
historical controls diagnosed in the year 2003 (174 cases)
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We tested peripheral blood leukocytes for their memory
capacity by proliferation assays in two patients (nos. 10 and
16) by recalling reactivity against autologous tumor
extract. Ten months after transfusion we detected prolif-
eration and secretion of IFN-c in response to autologous
tumor extract (Fig. 4a–c), indicating the presence of
memory cells. Peripheral blood leukocytes from patient no.
16 were again tested for proliferation against autologous
tumor extract 42 months after treatment. Interestingly an
increased recall proliferation was noticed after 42 months
(47,000 cpm) as compared with responses seen after
10 months (10,000 cpm) (Fig. 4c, d), suggesting that
expansion of a long-lived memory cell population occurred
in vivo. When these cells were tested for proliferation
against allogeneic tumor extract from patient 5, a recall
response was noted, albeit at a lower level, suggesting that
common tumor antigens are present in these tumor prepa-
rations (Fig. 4d).
DISCUSSION
We have previously identiﬁed the localized presence of
immune responses against the autologous tumor in senti-
nel nodes draining colorectal and urinary bladder
cancers.
12–14 In the present study, sentinel-node-acquired
lymphocytes were expanded ex vivo against an autolo-
gous tumor extract and retransfused to 16 patients with
colorectal cancer.
In theory, processing and presentation of exogenous
intact antigens via endocytosis favors loading of the major
histocompatibility complex (MHC) class II pocket, thus
mediating clonal expansion of class II restricted tumor-
reactive CD4
? T-helper lymphocytes. This also appeared
to be the case, as evidenced by an increased CD4/CD8 ratio
in the majority of cell cultures (Table 1). However, in some
cases a signiﬁcant expansion of CD8
? cytotoxic T-cells
was observed, most likely the result of cross-presentation
of extracellular antigens on MHC class I molecules.
25 The
expanded cell populations displayed the surface phenotype
of memory cells (Fig. 2a) and a cytokine secretion proﬁle
of Th1-cells (Fig. 2c). Both central (CD62L-positive) and
effector (CD62L-negative) cells were present in the trans-
fused cell populations (Fig. 2a). Whereas effector memory
cells are capable of executing immediate effector functions
upon antigen encounter, central memory cells home to
lymph nodes and may provide a lifelong source of new
effector cells, both upon secondary stimulation and under
the inﬂuence of homeostatic cytokines.
26,27 Indeed, both
proliferation and IFN-c secretion in response to tumor
extract could be detected in peripheral blood 10–42 months
after treatment (Fig. 4a–d).
On average, 71 million clonally expanded lymphocytes
were used in the adoptive transfers, which is a relatively
small number compared with protocols using primarily
CD8
? cytotoxic T-cells.
28 We consider this justiﬁable,
since as few as 3 9 10
5 adoptively transferred, antigen-
speciﬁc CD4
? Th1-cells are able to mediate tumor
regression in mice, mainly through recruitment and
expansion of host CD8
? T-cells.
29 Indeed, four patients
with distant metastases (stage IV) displayed complete
tumor regression after treatment with sentinel-node-
acquired lymphocytes. However, the ﬁve stage IV patients
with PR or SD all received lymphocytes in the lower range
(Fig. 3a), suggesting overwhelming immunosuppression
from their residual metastatic disease. Even when an
antitumoral response is induced by transfer of tumor-
reactive CD4
? Th1-lymphocytes, tumor cells may escape
elimination by losing targeted antigens, rendering T-cells
anergic by downregulation of costimulatory molecules, by
inducing regulatory T-lymphocytes, or by speciﬁcally
deleting responding T-lymphocytes.
30–33 The tumor that
ﬁnally develops may reﬂect a selection of poorly immu-
nogenic and/or immune-resistant malignant cells.
34 Tumor-
induced immunomodulation may not be limited to the
tumor microenvironment. Indeed, immunosuppression has
been identiﬁed also in lymphocytes from sentinel nodes,
which has been suggested to facilitate lymph node metas-
tases.
35 However, our method appears to reconstitute the
function of tumor-reactive CD4
? Th1-lymphocytes and
provide a large number of functioning tumor-reactive T-
lymphocytes, resulting in large antitumoral responses in
patients receiving large numbers of tumor-reactive T-cells.
Thus, an iterated therapy may be advocated, especially in
the presence of a signiﬁcant tumor burden.
Life expectancy in stage IV patients is 8–12 months.
36
Even though the cumulative survival was not signiﬁcantly
different from in conventionally treated controls, likely due
to the limited number of patients included in our study, the
median survival of 2.6 years in the nine immunotherapy-
treated stage IV patients is encouraging (Fig. 4e). The
possibility of receiving immunotherapy tended to select
patients hesitant to subject themselves to chemotherapy,
and therefore the overall amount of chemotherapy used
was low. Most patients received only immunotherapy (as
described in the ‘‘Methods’’ section). Among the four
complete responders, two patients (nos. 14 and 16)
received chemotherapy in association with immunother-
apy, whereas the other two patients had chemotherapy over
1 year prior to immunotherapy (patients no. 13 and 15).
Thus, the clinical results among immunotherapy-treated
stage IV patients are unlikely due to chemotherapy. The-
oretically, chemotherapy is a two-edged sword.
Chemotherapy may decrease the proliferative capability of
tumor-reactive T-cells since chemotherapy affects dividing
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On the other hand, when chemotherapy is administered, the
increased tumor cell death will result in increased antigen
presentation to T-lymphocytes, thus increased T-cell
reactivity may occur, as discussed in a recent review.
37 It
would be interesting to test immunotherapy and chemo-
therapy in combination in a future systematic study.
To our knowledge, sentinel-node-based immunotherapy
in patients with colon cancer is a novel approach. There are
some major differences between our study and others that
use anti-CD3/anti-CD28 expanded tumor-inﬁltrating lym-
phocytes, myeloablation, and high-dose IL-2.
28 Firstly, we
use sentinel-node-acquired lymphocytes providing a natu-
ral antitumoral response, enhanced by ex vivo stimulation
with autologous tumor homogenate, physiological doses of
IL-2, and restimulation with autologous antigen-presenting
cells (APCs) on one occasion after about 3 weeks of
expansion. Only T-lymphocytes with high afﬁnity to anti-
gens from the primary tumor will survive until transfusion.
Secondly, myeloablation and high-dose IL-2 regimen entail
high toxicity and bring along risk of severe complications,
long treatment periods, and high costs. Our transfusions,
however, were given without complications, during a per-
iod of 1 h, with patients often discharged the same day.
Thirdly, our protocol aims at expansion of CD4
? Th1-
lymphocytes from sentinel nodes, as opposed to expansion
of cytotoxic CD8
? T-lymphocytes harvested as tumor-
inﬁltrating lymphocytes.
In a recent retrospective analysis of resected tumors and
lymph nodes from patients with colorectal cancer, the
inﬂuence of immune cells on the advancement and out-
come of disease was investigated.
24 Increased numbers of
memory effector cells, Th1 activation as indicated by
increased messenger RNA (mRNA) for IFN-c, as well as
presence of the Th1-inducing transcription factor T-bet
within the tumor were all associated with absence of early
metastatic invasion and correlated strongly with prolonged
survival. Notably, the patients in our study were treated
with the same population of Th1-lymphocytes. Interest-
ingly, a recent experimental mouse model supports the
efﬁcacy of CD4
? T-helper lymphocytes in adoptive
immunotherapy. Mice with established tumors were treated
with adoptive transfer using in vitro activated T-lympho-
cytes harvested from tumor-draining lymph nodes. The
results demonstrated that expanded sorted CD4
? T-helper
lymphocytes from the tumor-draining lymph node have
therapeutic efﬁcacy on their own, and a synergistic effect
was found when CD4
? T-helper lymphocytes were used in
combination with expanded cytotoxic CD8
? T-lympho-
cytes.
38 In addition, adoptive transfer of a tumor antigen-
speciﬁc CD4
? T-cell clone to one patient with metastatic
malignant melanoma was recently reported to induce a 2-
month clinical remission.
39 In the light of these ﬁndings,
future trials using sentinel-node-acquired CD4
? and CD8
?
T-lymphocytes, raised separately under optimal conditions,
may further improve the outcome of sentinel-node-based
adaptive immunotherapy.
In conclusion, our study shows the novel ﬁnding that
freshly isolated sentinel-node-acquired lymphocytes pos-
sess proliferative ability ex vivo against autologous tumor
homogenate and may be retransfused to the patient without
complications, as adoptive immunotherapy. Our results
indicate that this cell population is capable of inducing
tumor regression in patients with disseminated colorectal
cancer. Due to its generic design, i.e., identiﬁcation of
sentinel node, isolation of tumor-reactive lymphocytes, and
ex vivo expansion, this method may be used to treat other
types of disseminated solid cancers.
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